(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 September 2014 (18.09.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/141038 A2

(51) International Patent Classification:
G01N 33/574 (2006.01)

(21) International Application Number:
PCT/IB2014/059585

(22) International Filing Date:
10 March 2014 (10.03.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/776,334 11 March 2013 (11.03.2013) US

(71) Applicant *(for all designated States except US)*: **IRM LLC**; 131 Front Street, P.O. Box HM 2899, Hamilton HM LX, 2899 (BM).

(72) Inventors; and

(71) Applicants *(for US only)*: **CHE, Jianwei** [US/US]; c/o Novartis Institute for Functional Genomics, Inc., 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). **HARRIS, Jennifer** [US/US]; c/o Novartis Institute for Functional Genomics, Inc., 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). **HSIN-I HSIEH, Mindy** [—/US]; c/o Novartis Institute for Functional Genomics, Inc., 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). **LI, Jie** [CN/US]; c/o Novartis Institute for Functional Genomics, Inc., 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). **LIU, Jun** [CN/US]; c/o Novartis Institute for Functional Genomics, Inc., 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). **NG, Nicholas** [US/US]; c/o Novartis Institute for Functional Genomics, Inc., 10675 John Jay Hopkins Drive, San Diego, California 92121 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,

[Continued on next page]

(54) Title: MARKERS ASSOCIATED WITH WNT INHIBITORS


FIGURE 1

1A



COMPOUND A

1B



COMPOUND B

(57) Abstract: The invention provides methods of monitoring differential gene expression of biomarkers to determine patient sensitivity to Wnt inhibitor, methods of determining the sensitivity of a cell to an Wnt inhibitor by measuring biomarkers, methods of screening for candidate Wnt inhibitor, Wnt inhibitor for use in head and neck squamous cell carcinoma.

WO 2014/141038 A2

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*